SE520177C2 - Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller - Google Patents

Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller

Info

Publication number: SE520177C2
Authority: SE; Sweden
Prior art keywords: cells; parvovirus; antigen; capsids; medicament
Prior art date: 1998-11-24

Application number

SE9804022A

Other languages

English (en)

Swedish (sv)

Other versions

SE9804022L (sv

SE9804022D0 (sv

Inventor

Kristina Broliden

Magnus Westgren

Original Assignee

Kristina Broliden

Magnus Westgren

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-24

Filing date

1998-11-24

Publication date

2003-06-03

1998-11-24 Application filed by Kristina Broliden, Magnus Westgren filed Critical Kristina Broliden

1998-11-24 Priority to SE9804022A priority Critical patent/SE520177C2/sv

1998-11-24 Publication of SE9804022D0 publication Critical patent/SE9804022D0/xx

1999-11-23 Priority to PL99348640A priority patent/PL348640A1/xx

1999-11-23 Priority to PCT/IB1999/002112 priority patent/WO2000030668A2/en

1999-11-23 Priority to HU0104298A priority patent/HUP0104298A2/hu

1999-11-23 Priority to MXPA01004949A priority patent/MXPA01004949A/es

1999-11-23 Priority to JP2000583551A priority patent/JP2003516927A/ja

1999-11-23 Priority to KR1020017006374A priority patent/KR20010080518A/ko

1999-11-23 Priority to CA002352043A priority patent/CA2352043A1/en

1999-11-23 Priority to AU25666/00A priority patent/AU2566600A/en

1999-11-23 Priority to EP99968407A priority patent/EP1131085A2/en

1999-11-23 Priority to CN99813653A priority patent/CN1328469A/zh

1999-11-23 Priority to CZ20011369A priority patent/CZ20011369A3/cs

2000-05-25 Publication of SE9804022L publication Critical patent/SE9804022L/

2001-05-02 Priority to IS5931A priority patent/IS5931A/is

2001-05-23 Priority to NO20012534A priority patent/NO20012534L/no

2001-11-16 Priority to US09/991,433 priority patent/US6818612B2/en

2002-07-19 Priority to US10/200,616 priority patent/US6743772B1/en

2003-06-03 Publication of SE520177C2 publication Critical patent/SE520177C2/sv

2004-03-02 Priority to US10/792,640 priority patent/US20060141477A1/en

Links

210000000234 capsid Anatomy 0.000 title claims abstract description 63
239000003814 drug Substances 0.000 title claims abstract description 16
239000002245 particle Substances 0.000 title claims abstract description 13
210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 10
238000004519 manufacturing process Methods 0.000 title claims abstract description 5
230000002401 inhibitory effect Effects 0.000 title claims description 14
208000015181 infectious disease Diseases 0.000 title claims description 10
230000002458 infectious effect Effects 0.000 title claims description 9
229940079593 drug Drugs 0.000 title 1
210000004027 cell Anatomy 0.000 claims abstract description 51
241000125945 Protoparvovirus Species 0.000 claims abstract description 13
230000010261 cell growth Effects 0.000 claims abstract description 9
238000011476 stem cell transplantation Methods 0.000 claims abstract description 7
210000002889 endothelial cell Anatomy 0.000 claims abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 9
210000003754 fetus Anatomy 0.000 claims description 7
208000017733 acquired polycythemia vera Diseases 0.000 claims description 4
230000002489 hematologic effect Effects 0.000 claims description 4
208000037244 polycythemia vera Diseases 0.000 claims description 4
230000002062 proliferating effect Effects 0.000 claims description 4
239000000427 antigen Substances 0.000 abstract description 9
102000036639 antigens Human genes 0.000 abstract description 8
108091007433 antigens Proteins 0.000 abstract description 8
239000000203 mixture Substances 0.000 abstract description 8
238000000034 method Methods 0.000 abstract description 4
230000003394 haemopoietic effect Effects 0.000 abstract description 3
108090000565 Capsid Proteins Proteins 0.000 abstract 1
102100023321 Ceruloplasmin Human genes 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
230000002622 anti-tumorigenesis Effects 0.000 abstract 1
230000003176 fibrotic effect Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000002513 implantation Methods 0.000 abstract 1
238000013508 migration Methods 0.000 abstract 1
230000005012 migration Effects 0.000 abstract 1
230000017066 negative regulation of growth Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
241000702617 Human parvovirus B19 Species 0.000 description 44
230000001605 fetal effect Effects 0.000 description 20
239000002609 medium Substances 0.000 description 17
230000005757 colony formation Effects 0.000 description 16
210000005229 liver cell Anatomy 0.000 description 14
230000000694 effects Effects 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
210000000130 stem cell Anatomy 0.000 description 8
210000003013 erythroid precursor cell Anatomy 0.000 description 7
230000001332 colony forming effect Effects 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
210000004700 fetal blood Anatomy 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
241000700605 Viruses Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
241000701646 Kappapapillomavirus 2 Species 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
210000003593 megakaryocyte Anatomy 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
206010068051 Chimerism Diseases 0.000 description 2
208000034423 Delivery Diseases 0.000 description 2
208000007985 Erythema Infectiosum Diseases 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241001631646 Papillomaviridae Species 0.000 description 2
206010000210 abortion Diseases 0.000 description 2
231100000176 abortion Toxicity 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010293 colony formation assay Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000003643 myeloid progenitor cell Anatomy 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
101710197658 Capsid protein VP1 Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
241001428582 Human papillomavirus type 6 Species 0.000 description 1
241000484121 Human parvovirus Species 0.000 description 1
101900151434 Human parvovirus B19 Minor capsid protein VP1 Proteins 0.000 description 1
239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
101710081079 Minor spike protein H Proteins 0.000 description 1
241000334993 Parma Species 0.000 description 1
101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
101710108545 Viral protein 1 Proteins 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
210000000604 fetal stem cell Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000001400 myeloablative effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
108010003087 parvovirus B19 capsid protein VP2 Proteins 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000009677 vaginal delivery Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Virology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Surgery (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SE9804022A 1998-11-24 1998-11-24 Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller SE520177C2 (sv)

Priority Applications (17)

Application Number	Priority Date	Filing Date	Title
SE9804022A SE520177C2 (sv)	1998-11-24	1998-11-24	Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller
CZ20011369A CZ20011369A3 (cs)	1998-11-24	1999-11-23	Pouľití prázdných, neinfekčních, rekombinantních kapsid parvoviru B 19, způsob potlačení růstu nebo migrace buňky, způsoby léčby pacienta a potlačení tkáňového vrůstání, kit, lékařský prostředek a pouľití kapsid parvoviru B 19
AU25666/00A AU2566600A (en)	1998-11-24	1999-11-23	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
CN99813653A CN1328469A (zh)	1998-11-24	1999-11-23	细小病毒衣壳颗粒抑制细胞增生及迁移的用途
HU0104298A HUP0104298A2 (hu)	1998-11-24	1999-11-23	Parvovíruskapszid-részecskék alkalmazása a sejtproliferáció és -migráció gátlására
MXPA01004949A MXPA01004949A (es)	1998-11-24	1999-11-23	Uso de particulas de capside de parvovirus en la inhibicion de la proliferacion y la migracion celular.
JP2000583551A JP2003516927A (ja)	1998-11-24	1999-11-23	細胞増殖および移動の抑制におけるパルボウイルスキャプシド粒子の使用
KR1020017006374A KR20010080518A (ko)	1998-11-24	1999-11-23	세포 증식 및 세포 이동의 억제에 대한 파르보바이러스캡시드 입자의 용도
CA002352043A CA2352043A1 (en)	1998-11-24	1999-11-23	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
PL99348640A PL348640A1 (en)	1998-11-24	1999-11-23	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
EP99968407A EP1131085A2 (en)	1998-11-24	1999-11-23	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
PCT/IB1999/002112 WO2000030668A2 (en)	1998-11-24	1999-11-23	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
IS5931A IS5931A (is)	1998-11-24	2001-05-02	Notkun smáveiruhjúphluta til að hamla frumufjölgun og frumuflutningi
NO20012534A NO20012534L (no)	1998-11-24	2001-05-23	Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migrering
US09/991,433 US6818612B2 (en)	1998-11-24	2001-11-16	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
US10/200,616 US6743772B1 (en)	1998-11-24	2002-07-19	Use of parovirus capsid particles in the inhibition of cell proliferation and migration
US10/792,640 US20060141477A1 (en)	1998-11-24	2004-03-02	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9804022A SE520177C2 (sv)	1998-11-24	1998-11-24	Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller

Publications (3)

Publication Number	Publication Date
SE9804022D0 SE9804022D0 (sv)	1998-11-24
SE9804022L SE9804022L (sv)	2000-05-25
SE520177C2 true SE520177C2 (sv)	2003-06-03

Family

ID=20413393

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9804022A SE520177C2 (sv)	1998-11-24	1998-11-24	Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller

Country Status (14)

Country	Link
EP (1)	EP1131085A2 (is)
JP (1)	JP2003516927A (is)
KR (1)	KR20010080518A (is)
CN (1)	CN1328469A (is)
AU (1)	AU2566600A (is)
CA (1)	CA2352043A1 (is)
CZ (1)	CZ20011369A3 (is)
HU (1)	HUP0104298A2 (is)
IS (1)	IS5931A (is)
MX (1)	MXPA01004949A (is)
NO (1)	NO20012534L (is)
PL (1)	PL348640A1 (is)
SE (1)	SE520177C2 (is)
WO (1)	WO2000030668A2 (is)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1275658B1 (en) *	2001-07-10	2006-11-15	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis
EP2149583B1 (en) *	2004-09-24	2015-10-28	Novartis AG	Modified VP1-capsid protein of parvovirus B19
CN101475942B (zh) *	2008-11-28	2012-05-23	中国人民解放军第四军医大学	一种b19病毒vp1独特区基因
WO2012159006A2 (en) *	2011-05-18	2012-11-22	University Of Florida Research Foundation, Inc.	Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2755817B2 (ja) *	1988-11-14	1998-05-25	アメリカ合衆国	パルボウイルスキャプシド
NL8902301A (nl) *	1989-09-14	1991-04-02	Rijksuniversiteit	Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.

1998
- 1998-11-24 SE SE9804022A patent/SE520177C2/sv not_active IP Right Cessation
1999
- 1999-11-23 CZ CZ20011369A patent/CZ20011369A3/cs unknown
- 1999-11-23 MX MXPA01004949A patent/MXPA01004949A/es unknown
- 1999-11-23 PL PL99348640A patent/PL348640A1/xx unknown
- 1999-11-23 HU HU0104298A patent/HUP0104298A2/hu unknown
- 1999-11-23 WO PCT/IB1999/002112 patent/WO2000030668A2/en not_active Ceased
- 1999-11-23 EP EP99968407A patent/EP1131085A2/en not_active Withdrawn
- 1999-11-23 JP JP2000583551A patent/JP2003516927A/ja active Pending
- 1999-11-23 AU AU25666/00A patent/AU2566600A/en not_active Abandoned
- 1999-11-23 KR KR1020017006374A patent/KR20010080518A/ko not_active Withdrawn
- 1999-11-23 CN CN99813653A patent/CN1328469A/zh active Pending
- 1999-11-23 CA CA002352043A patent/CA2352043A1/en not_active Abandoned
2001
- 2001-05-02 IS IS5931A patent/IS5931A/is unknown
- 2001-05-23 NO NO20012534A patent/NO20012534L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1328469A (zh)	2001-12-26
SE9804022L (sv)	2000-05-25
MXPA01004949A (es)	2003-03-10
HUP0104298A2 (hu)	2002-03-28
CA2352043A1 (en)	2000-06-02
SE9804022D0 (sv)	1998-11-24
JP2003516927A (ja)	2003-05-20
IS5931A (is)	2001-05-02
KR20010080518A (ko)	2001-08-22
WO2000030668A2 (en)	2000-06-02
WO2000030668A9 (en)	2001-04-05
WO2000030668A3 (en)	2000-11-09
EP1131085A2 (en)	2001-09-12
NO20012534L (no)	2001-06-29
AU2566600A (en)	2000-06-13
CZ20011369A3 (cs)	2001-10-17
PL348640A1 (en)	2002-06-03
NO20012534D0 (no)	2001-05-23
WO2000030668A8 (en)	2000-09-14

Legal Events

Date	Code	Title	Description
2010-06-29	NUG	Patent has lapsed

Publication	Publication Date	Title
Andreani et al.	2010	Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease
Singbrant et al.	2011	Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment
Brown et al.	1996	Parvoviruses and bone marrow failure
KR20230050355A (ko)	2023-04-14	줄기세포를 동원하기 위한 방법 및 조성물
JP2023060299A (ja)	2023-04-27	敗血症の治療のための、ワルトンジェリーから取得された間葉系幹細胞
Ekhterae et al.	1990	Retroviral vector-mediated transfer of the bacterial neomycin resistance gene into fetal and adult sheep and human hematopoietic progenitors in vitro
Weil et al.	1997	Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer
Murphy et al.	2012	In vitro aspects of erythropoiesis
SE520177C2 (sv)	2003-06-03	Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller
US20190000885A1 (en)	2019-01-03	Treatment with angiogenin to enhance hematopoietic reconstitution
Lindton et al.	2001	Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro
WO2025082103A1 (zh)	2025-04-24	Cd146+间充质干细胞在制备预防和/或治疗脑卒中的药物中的用途
Tembe-Fokunang et al.	2022	The scope of aplastic anaemia: Etiology, pathophysiology, pharmacotherapy and Pharmacoeconomic impact in clinical patient management
US8765119B2 (en)	2014-07-01	Treating amyotrophic lateral sclerosis (ALS)with isolated aldehyde dehydrogenase-positive umbilical cord blood cells
US20230148432A1 (en)	2023-05-11	Use of stem cells for treatment of excessive inflammation
Banda et al.	1998	Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model
Young et al.	2018	Studies of the B19 virus in bone marrow cell culture
Norbeck et al.	2004	Parvovirus B19 capsid protein VP2 inhibits hematopoiesis in vitro and in vivo: implications for therapeutic use
Hartong et al.	2003	Co‐administration of Flt‐3 ligand counteracts the actions of thrombopoietin in myelosuppressed rhesus monkeys
US6743772B1 (en)	2004-06-01	Use of parovirus capsid particles in the inhibition of cell proliferation and migration
Ek et al.	1996	Cytokine stimulation of human fetal hematopoietic cells
KR101423659B1 (ko)	2014-07-28	초기 분화된 양수 줄기세포를 포함하는 요실금 치료제
US6818612B2 (en)	2004-11-16	Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
Merchav et al.	1985	Reconstitution of the W/W v stem cell differentiation defect by infection with Rauscher leukemia virus
US20050004037A1 (en)	2005-01-06	Osteogenic growth oligopeptides as stimulants of hematopoiesis